Compare ALEMBIC PHARMA with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs LUPIN - Comparison Results

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA LUPIN ALEMBIC PHARMA/
LUPIN
 
P/E (TTM) x 16.4 47.0 34.9% View Chart
P/BV x 6.5 4.3 150.9% View Chart
Dividend Yield % 0.6 0.5 116.6%  

Financials

 ALEMBIC PHARMA   LUPIN
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
LUPIN
Mar-20
ALEMBIC PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs664882 75.3%   
Low Rs412505 81.7%   
Sales per share (Unadj.) Rs208.7339.4 61.5%  
Earnings per share (Unadj.) Rs31.0-5.9 -521.3%  
Cash flow per share (Unadj.) Rs37.115.5 239.9%  
Dividends per share (Unadj.) Rs5.506.00 91.7%  
Dividend yield (eoy) %1.00.9 118.1%  
Book value per share (Unadj.) Rs144.2276.7 52.1%  
Shares outstanding (eoy) m188.52453.00 41.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.62.0 126.2%   
Avg P/E ratio x17.4-116.6 -14.9%  
P/CF ratio (eoy) x14.544.8 32.3%  
Price / Book Value ratio x3.72.5 148.9%  
Dividend payout %17.7-100.9 -17.6%   
Avg Mkt Cap Rs m101,461314,201 32.3%   
No. of employees `000NA18.3 0.0%   
Total wages/salary Rs m7,46729,868 25.0%   
Avg. sales/employee Rs ThNM8,400.6-  
Avg. wages/employee Rs ThNM1,632.0-  
Avg. net profit/employee Rs ThNM-147.2-  
INCOME DATA
Net Sales Rs m39,347153,748 25.6%  
Other income Rs m944,838 1.9%   
Total revenues Rs m39,441158,585 24.9%   
Gross profit Rs m8,73624,849 35.2%  
Depreciation Rs m1,1529,702 11.9%   
Interest Rs m1843,630 5.1%   
Profit before tax Rs m7,49316,355 45.8%   
Minority Interest Rs m114 276.9%   
Prior Period Items Rs m-9339 -235.5%   
Extraordinary Inc (Exp) Rs m0-7,521 0.0%   
Tax Rs m1,56811,571 13.5%   
Profit after tax Rs m5,844-2,694 -216.9%  
Gross profit margin %22.216.2 137.4%  
Effective tax rate %20.970.8 29.6%   
Net profit margin %14.9-1.8 -847.6%  
BALANCE SHEET DATA
Current assets Rs m19,577154,132 12.7%   
Current liabilities Rs m14,89692,252 16.1%   
Net working cap to sales %11.940.2 29.6%  
Current ratio x1.31.7 78.7%  
Inventory Days Days9082 109.3%  
Debtors Days Days45129 35.1%  
Net fixed assets Rs m27,09789,082 30.4%   
Share capital Rs m377906 41.6%   
"Free" reserves Rs m26,811124,461 21.5%   
Net worth Rs m27,188125,367 21.7%   
Long term debt Rs m4,99317,933 27.8%   
Total assets Rs m47,778249,839 19.1%  
Interest coverage x41.75.5 757.4%   
Debt to equity ratio x0.20.1 128.4%  
Sales to assets ratio x0.80.6 133.8%   
Return on assets %12.60.4 3,367.9%  
Return on equity %21.5-2.1 -1,000.3%  
Return on capital %23.68.7 270.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,45351,450 37.8%   
Fx outflow Rs m6,06519,470 31.1%   
Net fx Rs m13,38831,980 41.9%   
CASH FLOW
From Operations Rs m8,12014,688 55.3%  
From Investments Rs m-7,55611,070 -68.3%  
From Financial Activity Rs m590-8,906 -6.6%  
Net Cashflow Rs m1,15316,853 6.8%  

Share Holding

Indian Promoters % 74.1 46.6 159.0%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 2.9 11.3 25.7%  
FIIs % 9.1 31.9 28.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 10.1 137.6%  
Shareholders   49,328 98,259 50.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   FDC  UNICHEM LAB  PROCTER & GAMBLE HEALTH  AJANTA PHARMA  ALEMBIC  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 272 Points Higher; Hindalco, Hero MotoCorp & Wipro Surge Over 4%(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended higher.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

Power Grid's InvIT IPO: Key Points to Consider(Company Info)

Apr 23, 2021

In this article, we discuss the key reasons why the stock of Power Grid was in focus today.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


May 6, 2021 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS